Sunday, September 15, 2013

The Motley Fool: Johnson & Johnson Looks To Turn The Fading Ortho Diagnostics Unit Into Cash

While Foolish readers know all too well that a good turnaround story can drive excellent shareholders, sometimes discretion is the better part of valor and it makes more sense to just get out and move on. That is the attitude of Johnson & Johnson (NYSE: JNJ  )  with respect to its Ortho Clinical Diagnostics, or OCD, business, with the company openly acknowledging that it has begun discussions to sell this long-underperforming unit.

Continue here for the full article:

No comments: